Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor

被引:59
|
作者
Barnett-Norris, J
Hurst, DP
Lynch, DL
Guarnieri, F
Makriyannis, A
Reggio, PH
机构
[1] Kennesaw State Univ, Dept Chem & Biochem, Kennesaw, GA 30144 USA
[2] Sarnoff Corp, Princeton, NJ 08543 USA
[3] Univ Connecticut, Sch Pharm, Storrs, CT 06269 USA
关键词
D O I
10.1021/jm0200761
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Endocannabinoid stucture-activity relationships (SAR) indicate that the CB1 receptor recognizes ethanolamides whose fatty acid acyl chains have 20 or 22 carbons, with at least three homoallylic double bonds and saturation in at least the last five carbons of the acyl chain. To probe the molecular basis for these acyl chain requirements, the method of conformational memories (CM) was used to study the conformations available to an n-6 series of ethanolamide fatty acid acyl chain congeners: 22:4, n-6 (K-i = 34.4 +/- 13.2 nM); 20:4, n-6 (K-i = 39.2 +/- 5.7 nM); 20:3, n-6 (K-i = 53.4 +/- 5.5 nM); and 20:2, n-6 (K-i > 1500 nM). CM studies indicated that each analogue could form both extended and U/J-shaped families of conformers. However, for the low affinity 20:2, n-6 ethanolamide, the higher populated family was the extended conformer family, while for the other analogues in the series, the U/J-shaped family had the higher population. In addition, the 20:2, n-6 ethanolamide U-shaped family was not as tightly curved as were those of the other analogues studied. To quantitate this variation in curvature, the radius of curvature (in the C-3 to C-17 region) of each member of each U/J-shaped family was measured. The average radii of curvature (with their 95% confidence intervals) were found to be 5.8 Angstrom (5.3-6.2) for 20:2, n-6; 4.4 Angstrom (4.1-4.7) for 20:3, n-6; 4.0 Angstrom (3.7-4.2) for 20:4, n-6; and 4.0 Angstrom (3.6-4.5) for 22:4, n-6. These results suggest that higher CB1 affinity is associated with endocannabinoids that can form tightly curved structures. Endocannabinoid SAR also indicate that the CB1 receptor does not tolerate large endocannabinoid headgroups; however, it does recognize both polar and nonpolar moieties in the headgroup region. To identify a headgroup orientation that results in high CB1 affinity, a series of dimethyl anandamide analogues (R)N-(1-methyl-2-hydroxyethyl)-2-(R)-methyl-arachidonamide (K-i 7.42 +/- 0.86 nM), (R)-N-(1-methyl-2-hydroxyethyl)-2-(S)-methyl-arachidonamide (K-i 185 +/- 12 nM), (S)-N-(1-methyl-2hydroxyethyl)-2-(S)-methyl-arachidonamide (K-i = 389 +/- 72 nM), and (S)-N-(1-methyl-2hydroxyethyl)-2-(R)-methyl-arachidonamide (K-i = 233 +/- 69 nM) were then studied using CM and computer receptor docking studies in an active state (R*) model of CB1. These studies suggested that the high CB1 affinity of the RR stereoisomer is due to the ability of the headgroup to form an intramolecular hydrogen bond between the carboxamide oxygen and the headgroup hydroxyl that orients the C2 and C1' methyl groups to have hydrophobic interactions with valine 3.32(196), while the carboxamide oxygen forms a hydrogen bond with lysine 3.28(192) at CB1. In this position in the CB1 binding pocket, the acyl chain has hydrophobic and C-H...pi interactions with residues in the transmembrane helix (TMH) 2-3-7 region. Taken together, the studies reported here suggest that anandamide and its congeners adopt tightly curved U/J-shaped conformations at CB1 and suggest that the TMH 2-3-7 region is the endocannabinoid binding region at CB1.
引用
收藏
页码:3649 / 3659
页数:11
相关论文
共 50 条
  • [41] Cannabinoid CB1 Receptor and Gastric Acid Secretion
    Francesca Borrelli
    Digestive Diseases and Sciences, 2007, 52 : 3102 - 3103
  • [42] Preclinical Evaluation of Neutral Cannabinoid CB1 Receptor Antagonists and Cannabinoid CB1 Receptor Negative Allosteric Modulators for Treating Drug Addiction
    Gardner, Eliot L.
    Bi, Guo-Hua
    Thakur, Ganesh
    Makriyannis, Alexandros
    Seltzman, Herbert H.
    He, Xiang-Hu
    Xi, Zheng-Xiong
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 152 - 152
  • [43] Role of the cannabinoid receptor 1 (CB1) in fear adaptation
    Wotjak, Carsten T.
    ALCOHOL, 2011, 45 (03) : 270 - 270
  • [44] No changes in cannabinoid CB1 receptor binding density in the superior temporal gyrus in schizophrenia
    Deng, C.
    Han, M.
    Newell, K. A.
    Huang, X. F.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 308 - 309
  • [45] Promotion of Hepatocarcinogenesis by the Endocannabinoid Anandamide and its Receptor CB1
    Suk, Ki Tae
    Mederacke, Ingmar
    Gwak, Geum Youn
    Schwabe, Robert F.
    HEPATOLOGY, 2015, 62 : 1161A - 1161A
  • [46] Tuning the endocannabinoid system:: allosteric modulators of the CB1 receptor
    Ross, R. A.
    BRITISH JOURNAL OF PHARMACOLOGY, 2007, 152 (05) : 565 - 566
  • [47] The endocannabinoid CB1 receptor modulates retinal projection development
    Argaw, A.
    Duff, G.
    Ptito, M.
    Bouchard, J. -F.
    JOURNAL OF NEUROLOGY, 2009, 256 : S196 - S197
  • [48] Reply to "The endocannabinoid 2-arachidonoylglycerol inhibits endothelial function and repair through cannabinoid 1 (CB1) receptor"
    Jehle, Julian
    Eich, Lukas
    Noethel, Moritz
    Avraamidou, Elina
    Pfeifer, Philipp
    Nickenig, Georg
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 330 : 178 - 178
  • [49] Specific detection of CB1 receptors;: cannabinoid CB1 receptor antibodies are not all created equal!
    Grimsey, Natasha L.
    Goodfellow, Catherine E.
    Scotter, Emma L.
    Dowie, Megan J.
    Glass, Michelle
    Graham, E. Scott
    JOURNAL OF NEUROSCIENCE METHODS, 2008, 171 (01) : 78 - 86
  • [50] Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors
    Merighi, Stefania
    Simioni, Carolina
    Gessi, Stefania
    Varani, Katia
    Borea, Pier Andrea
    BIOCHEMICAL PHARMACOLOGY, 2010, 79 (03) : 471 - 477